{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:00:56Z","timestamp":1785495656011,"version":"3.56.0"},"reference-count":60,"publisher":"Akademiai Kiado Zrt.","issue":"50","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2025,12,14]]},"abstract":"\n Bevezet\u00e9s:<\/jats:italic>\n A kalcitoning\u00e9nnel kapcsolatos peptid (CGRP-) \u00fatvonal\n g\u00e1tl\u00e1sa \u00faj ter\u00e1pi\u00e1s lehet\u0151s\u00e9get k\u00edn\u00e1l a migr\u00e9nes rohamok megel\u0151z\u00e9s\u00e9ben.\n C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n A jelen vez\u00e9rfonal c\u00e9lja, hogy gyakorlati\n \u00fatmutat\u00e1st adjon az epizodikus \u00e9s kr\u00f3nikus migr\u00e9nben alkalmazhat\u00f3 CGRP-g\u00e1tl\u00f3k\n biztons\u00e1gos, hat\u00e9kony \u00e9s szem\u00e9lyre szabott alkalmaz\u00e1s\u00e1hoz a magyarorsz\u00e1gi\n klinikai gyakorlatban.\n M\u00f3dszer:<\/jats:italic>\n A gyakorlati \u00fatmutat\u00e1sok a\n nemzetk\u00f6zi ir\u00e1nyelvek, valamint az aktu\u00e1lis klinikai vizsg\u00e1lati eredm\u00e9nyek\n alapj\u00e1n ker\u00fcltek kidolgoz\u00e1sra. Az aj\u00e1nl\u00e1s figyelembe veszi a gy\u00f3gyszerek\n hat\u00e1soss\u00e1g\u00e1t, mell\u00e9khat\u00e1sprofilj\u00e1t, kontraindik\u00e1ci\u00f3it, valamint a speci\u00e1lis\n betegcsoportokra vonatkoz\u00f3 szempontokat.\n Eredm\u00e9nyek \u00e9s\n javaslatok:<\/jats:italic>\n A CGRP-antagonist\u00e1k \u2013 bele\u00e9rtve a monoklon\u00e1lis\n antitesteket \u00e9s a gep\u00e1ntokat \u2013 hat\u00e1soss\u00e1guk \u00e9s kedvez\u0151 biztons\u00e1goss\u00e1gi profiljuk\n r\u00e9v\u00e9n els\u0151 vonalbeli kezel\u00e9sk\u00e9nt is alkalmazhat\u00f3k a migr\u00e9nroham kezel\u00e9s\u00e9ben \u00e9s\n megel\u0151z\u0151 kezel\u00e9s\u00e9ben, k\u00fcl\u00f6n\u00f6sen akkor, ha a beteg klinikai \u00e1llapota,\n preferenci\u00e1i vagy komorbidit\u00e1sai ezt indokolj\u00e1k. A monoklon\u00e1lis antitestek \u00e9s\n gep\u00e1ntok alkalmaz\u00e1sa sor\u00e1n a mell\u00e9khat\u00e1sok t\u00falnyom\u00f3r\u00e9szt enyh\u00e9k, a\n biztons\u00e1goss\u00e1g is kedvez\u0151. A ter\u00e1pi\u00e1s d\u00f6nt\u00e9st h\u00e1rom h\u00f3napos \u00e9rt\u00e9kel\u00e9si\n peri\u00f3dusnak kell k\u00f6vetnie, sikertelens\u00e9g eset\u00e9n pedig a gy\u00f3gyszerv\u00e1lt\u00e1s vagy a\n kombin\u00e1ci\u00f3s kezel\u00e9s esetlegesen m\u00e9rlegelend\u0151.\n K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n A\n struktur\u00e1lt ter\u00e1pi\u00e1s algoritmus \u00e9s a betegre szabott megk\u00f6zel\u00edt\u00e9s a nemzetk\u00f6zi\n ir\u00e1nyelvek szerint igazoltan kedvez\u0151 hat\u00e1s\u00fa lehet, \u00e9s v\u00e1rhat\u00f3an hozz\u00e1j\u00e1rul a\n migr\u00e9nes betegek \u00e9letmin\u0151s\u00e9g\u00e9nek javul\u00e1s\u00e1hoz. Orv Hetil. 2025; 166(50):\n 1963\u20131974.\n <\/jats:p>","DOI":"10.1556\/650.2025.33427","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T14:34:55Z","timestamp":1765722895000},"page":"1963-1974","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["A Magyarorsz\u00e1gi F\u00e1jdalom T\u00e1rsas\u00e1g Kr\u00f3nikus Fejf\u00e1j\u00e1s Munkacsoportja \u00e9s a Magyar Fejf\u00e1j\u00e1s T\u00e1rsas\u00e1g k\u00f6z\u00f6s gyakorlati \u00fatmutat\u00f3ja a kalcitoning\u00e9nnel kapcsolatos peptid (CGRP-) rendszerre hat\u00f3 gy\u00f3gyszerek alkalmaz\u00e1s\u00e1r\u00f3l epizodikus \u00e9s kr\u00f3nikus migr\u00e9nben"],"prefix":"10.1556","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8639-0219","authenticated-orcid":true,"given":"Gergely","family":"Feh\u00e9r","sequence":"first","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Foglalkoz\u00e1s-orvostani Int\u00e9zet P\u00e9cs, R\u00e1k\u00f3czi \u00fat 2., 7623 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9lia","family":"Szok","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Neurol\u00f3giai Klinika Szeged Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Tajti","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Neurol\u00f3giai Klinika Szeged Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Balogh","sequence":"additional","affiliation":[{"name":"Ny\u00edr\u0151 Gyula Orsz\u00e1gos Pszichi\u00e1triai \u00e9s Addiktol\u00f3giai Int\u00e9zet Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ron","family":"Bartha","sequence":"additional","affiliation":[{"name":"Petz Alad\u00e1r Egyetemi Oktat\u00f3 K\u00f3rh\u00e1z, Neurol\u00f3giai Oszt\u00e1ly Gy\u0151r Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilvia","family":"Ambrus","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, Fogorvostudom\u00e1nyi Kar, Fogp\u00f3tl\u00e1stani Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"Ertsey","sequence":"additional","affiliation":[{"name":"Swiss Clinic Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"\u00c1fra","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Idegseb\u00e9szeti \u00e9s Neurointervenci\u00f3s Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Judit","family":"Kelemen","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Neurol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levente","family":"Ker\u00e9nyi","sequence":"additional","affiliation":[{"name":"Fej\u00e9r V\u00e1rmegyei Szent Gy\u00f6rgy Egyetemi Oktat\u00f3 K\u00f3rh\u00e1z, Neurol\u00f3giai Oszt\u00e1ly Sz\u00e9kesfeh\u00e9rv\u00e1r Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Dong L, Dong W, Jin Y, et al. The global burden of migraine: a\n 30-year trend review and future projections by age, sex, country, and region.\n Pain Ther. 2025; 14: 297-315.\n https:\/\/doi.org\/10.1007\/s40122-024-00690-7","DOI":"10.1007\/s40122-024-00690-7"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Heinzlmann A, K\u00f6ves K. Clinical importance of adenylate\n cyclase-activating polypeptide (PACAP). [Az adenil\u00e1t-cikl\u00e1z-aktiv\u00e1l\u00f3 polipeptid\n (PACAP) klinikai jelent\u0151s\u00e9ge.] Orv Hetil. 2023; 164: 1300-1310. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2023.32833","DOI":"10.1556\/650.2023.32833"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"\u00d8ie LR, Kurth T, Gulati S, et al. Migraine and risk of stroke. J\n Neurol Neurosurg Psychiatry 2020; 91: 593-604.\n https:\/\/doi.org\/10.1136\/jnnp-2018-318254","DOI":"10.1136\/jnnp-2018-318254"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF)\n consensus on the definition of effective treatment of a migraine attack and of\n triptan failure. J Headache Pain 2022; 23: 133.\n https:\/\/doi.org\/10.1186\/s10194-022-01502-z","DOI":"10.1186\/s10194-022-01502-z"},{"key":"R5","unstructured":"Goadsby PJ, Holland PR, Robblee J, et al. Migraine therapeutics:\n from triptans to ditans and gepants. Lancet 2021; 397:\n 2089-2100."},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Edvinsson L. CGRP receptor antagonists and antibodies against CGRP\n and its receptor in migraine treatment. Br J Clin Pharmacol. 2015; 80: 193-199.\n https:\/\/doi.org\/10.1111\/bcp.12618","DOI":"10.1111\/bcp.12618"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Vendrell A, Campoy S, Caronna E, et al. Effectiveness and\n safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life\n multicentre analysis of 162 patients. J Headache Pain 2023; 24: 63.\n https:\/\/doi.org\/10.1186\/s10194-023-01585-2","DOI":"10.1186\/s10194-023-01585-2"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Edvinsson L, Warfvinge K. Recognizing the role of CGRP and CGRP\n receptors in migraine and its treatment. Cephalalgia 2019; 39: 366-373.\n https:\/\/doi.org\/10.1177\/0333102417736900","DOI":"10.1177\/0333102417736900"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache\n Society (IHS) The international classification of headache disorders, 3rd\n edition. Cephalalgia 2018; 38: 1-211.\n https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Torres-Ferr\u00fas M, Ursitti F, Alpuente A, et al. From transformation\n to chronification of migraine: pathophysiological and clinical aspects. J\n Headache Pain 2020; 21: 42.\n https:\/\/doi.org\/10.1186\/s10194-020-01111-8","DOI":"10.1186\/s10194-020-01111-8"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Buse DC, Muenzel EJ, Zagar AJ, et al. Rates and risk factors for\n migraine progression using multiple definitions of progression: results of the\n longitudinal OVERCOME (US) study. Headache 2025; 65: 589-607.\n https:\/\/doi.org\/10.1111\/head.14925","DOI":"10.1111\/head.14925"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Louter MA, Bosker JE, van Oosterhout WP, et al. Cutaneous allodynia\n as a predictor of migraine chronification. Brain 2013; 136: 3489-3496.\n https:\/\/doi.org\/10.1093\/brain\/awt251","DOI":"10.1093\/brain\/awt251"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Wang Q, Wang S, Zhu Y, et al. Clinical efficacy and safety of\n rimegepant in the treatment of migraine: a meta-analysis of randomized\n controlled trials. Front Neurol. 2023; 14: 1205778.\n https:\/\/doi.org\/10.3389\/fneur.2023.1205778","DOI":"10.3389\/fneur.2023.1205778"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Yang Y, Chen M, Sun Y, et al. Safety and efficacy of ubrogepant for\n the acute treatment of episodic migraine: a meta-analysis of randomized clinical\n trials. CNS Drugs 2020; 34: 463-471.\n https:\/\/doi.org\/10.1007\/s40263-020-00715-7","DOI":"10.1007\/s40263-020-00715-7"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Waqas M, Ansari FU, Nazir A, et al. Zavegepant nasal spray for the\n acute treatment of migraine: a meta-analysis. Medicine (Baltimore) 2023; 102:\n e35632. https:\/\/doi.org\/10.1097\/MD.0000000000035632","DOI":"10.1097\/MD.0000000000035632"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Versijpt J, Paemeleire K, Reuter U, et al. Calcitonin gene-related\n peptide-targeted therapy in migraine: current role and future perspectives.\n Lancet 2025; 405: 1014-1026. Erratum: Lancet 2025; 406: 134.\n https:\/\/doi.org\/10.1016\/S0140-6736(25)00109-6","DOI":"10.1016\/S0140-6736(25)00109-6"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Karlsson WK, Ostinelli EG, Zhuang ZA, et al. Comparative effects of\n drug interventions for the acute management of migraine episodes in adults:\n systematic review and network meta-analysis. BMJ 2024; 386: e080107.\n https:\/\/doi.org\/10.1136\/bmj-2024-080107","DOI":"10.1136\/bmj-2024-080107"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Ramsey RR, Ryan JL, Hershey AD, et al. Treatment adherence in\n patients with headache: a systematic review. Headache 2014; 54: 795-816.\n https:\/\/doi.org\/10.1111\/head.12353","DOI":"10.1111\/head.12353"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Laohapiboolrattana W, Jansem P, Anukoolwittaya P, et al. Efficacy of\n lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan\n insufficient responders: systematic review and network meta-analysis. J Headache\n Pain 2024; 25: 194.\n https:\/\/doi.org\/10.1186\/s10194-024-01904-1","DOI":"10.1186\/s10194-024-01904-1"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Ashina M, McAllister P, Cady R, et al. Efficacy and safety of\n eptinezumab in patients with migraine and self-reported aura: post hoc analysis\n of PROMISE-1 and PROMISE-2. Cephalalgia 2022; 42: 696-704.\n https:\/\/doi.org\/10.1177\/03331024221077646","DOI":"10.1177\/03331024221077646"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Feh\u00e9r G, Szok D, Ambrus JS, et al. Joint guideline of the Headache\n Working Group of the Hungarian Headache Society (MFT) and the Hungarian Pain\n Society (MOFT) for the practical care of acute and chronic migraine. [A Magyar\n Fejf\u00e1j\u00e1s T\u00e1rsas\u00e1g (MFT) \u00e9s a Magyarorsz\u00e1gi F\u00e1jdalom T\u00e1rsas\u00e1g (MOFT) Fejf\u00e1j\u00e1s\n Munkacsoportj\u00e1nak k\u00f6z\u00f6s vez\u00e9rfonala az akut \u00e9s kr\u00f3nikus migr\u00e9n gyakorlati\n ell\u00e1t\u00e1s\u00e1hoz.] Ideggy\u00f3gy Szle. 2024; 77: 368-378. [Hungarian]\n https:\/\/doi.org\/10.18071\/isz.77.0367","DOI":"10.18071\/isz.77.0367"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, et al. Evaluating the\n efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a\n systematic review and network meta-analysis of phase 3 randomised controlled\n trials. Cephalalgia 2023; 43: 3331024231159366. Erratum: Cephalalgia 2024; 44:\n 3331024241255216.\n https:\/\/doi.org\/10.1177\/03331024231159366","DOI":"10.1177\/03331024231159366"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Haseeb ME, Mohammed HE, Yaser H, et al. Unveiling the efficacy and\n safety of erenumab, a monoclonal antibody targeting calcitonin gene-related\n peptide (CGRP) receptor, in patients with chronic and episodic migraine: a\n GRADE-assessed systematic review and meta-analysis of randomized clinical trials\n with subgroup analysis. Head Face Med. 2025; 21: 19.\n https:\/\/doi.org\/10.1186\/s13005-025-00494-w","DOI":"10.1186\/s13005-025-00494-w"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Raja A, Asim R, Shuja MH, et al. Atogepant for migraine prevention:\n a meta-analysis of safety and efficacy in adults. Front Neurol. 2024; 15:\n 1468961. Erratum: Front Neurol. 2025; 16: 1577914.\n https:\/\/doi.org\/10.3389\/fneur.2024.1468961","DOI":"10.3389\/fneur.2024.1468961"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Zhong Y, Wang J, Li H, et al. Efficacy and safety of eptinezumab for\n migraine: a systematic review and meta-analysis. J Res Med Sci. 2023; 28: 82.\n https:\/\/doi.org\/10.4103\/jrms.jrms_306_22","DOI":"10.4103\/jrms.jrms_306_22"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Charles AC, Digre KB, Goadsby PJ, et al. Calcitonin gene-related\n peptide-targeting therapies are a first-line option for the prevention of\n migraine: an American Headache Society position statement update. Headache 2024;\n 64: 333-341. https:\/\/doi.org\/10.1111\/head.14692","DOI":"10.1111\/head.14692"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Sacco S, Amin FM, Ashina M, et al. European Headache Federation\n guideline on the use of monoclonal antibodies targeting the calcitonin gene\n related peptide pathway for migraine prevention - 2022 update. J Headache Pain\n 2022; 23: 67.\n https:\/\/doi.org\/10.1186\/s10194-022-01431-x","DOI":"10.1186\/s10194-022-01431-x"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Robblee J, Hakim SM, Reynolds JM, et al. Nonspecific oral\n medications versus anti-calcitonin gene-related peptide monoclonal antibodies\n for migraine: a systematic review and meta-analysis of randomized controlled\n trials. Headache 2024; 64: 547-572.\n https:\/\/doi.org\/10.1111\/head.14693","DOI":"10.1111\/head.14693"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. The comparative\n effectiveness of migraine preventive drugs: a systematic review and network\n meta-analysis. J Headache Pain 2023; 24: 56.\n https:\/\/doi.org\/10.1186\/s10194-023-01594-1","DOI":"10.1186\/s10194-023-01594-1"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Barbanti P, Aurilia C, Egeo G, et al. Ultra-late response (>24\n weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter,\n prospective, observational study. J Neurol. 2024; 271: 2434-2443. Erratum: J\n Neurol. 2024; 271: 2444-2445.\n https:\/\/doi.org\/10.1007\/s00415-023-12103-4","DOI":"10.1007\/s00415-023-12103-4"},{"key":"R31","unstructured":"Feh\u00e9r G, Szok D, Ambrus Sz, et al. Abbreviated joint guideline of\n the Hungarian Headache Society (MFT) and the Headache Working Group of the\n Hungarian Pain Society (MOFT) for the practical management of episodic and\n chronic migraine: 2025 update. [A Magyar Fejf\u00e1j\u00e1s T\u00e1rsas\u00e1g (MFT) \u00e9s a\n Magyarorsz\u00e1gi F\u00e1jdalom T\u00e1rsas\u00e1g (MOFT) Fejf\u00e1j\u00e1s Munkacsoportj\u00e1nak r\u00f6vid\u00edtett\n k\u00f6z\u00f6s vez\u00e9rfonala az epizodikus \u00e9s kr\u00f3nikus migr\u00e9n gyakorlati ell\u00e1t\u00e1s\u00e1hoz: 2025\n update.] Praxis 2025; 34: 31-38. [Hungarian]"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Messina R, Huessler EM, Puledda F, et al. Safety and tolerability of\n monoclonal antibodies targeting the CGRP pathway and gepants in migraine\n prevention: a systematic review and network meta-analysis. Cephalalgia 2023; 43:\n 3331024231152169.\n https:\/\/doi.org\/10.1177\/03331024231152169","DOI":"10.1177\/03331024231152169"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Al-Karagholi MA, Kalatharan V, Fagerberg PS, et al. The vascular\n role of CGRP: a systematic review of human studies. Front Neurol. 2023; 14:\n 1204734. https:\/\/doi.org\/10.3389\/fneur.2023.1204734","DOI":"10.3389\/fneur.2023.1204734"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Yang S, Orlova Y, Park H, et al. Cardiovascular safety of anti-CGRP\n monoclonal antibodies in older adults or adults with disability with migraine.\n JAMA Neurol. 2025; 82: 132-141.\n https:\/\/doi.org\/10.1001\/jamaneurol.2024.4537","DOI":"10.1001\/jamaneurol.2024.4537"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Eller MT, Frank F, Kaltseis K, et al. Novel calcitonin gene-related\n peptide (CGRP) interfering migraine therapies and stroke - a review. Int J Mol\n Sci. 2024; 25: 11685.\n https:\/\/doi.org\/10.3390\/ijms252111685","DOI":"10.3390\/ijms252111685"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Zhang S, Liu H, Shi T. Association between migraine and risk of\n stroke: a systematic review and meta-analysis. Neurol Sci. 2022; 43: 4875-4889.\n https:\/\/doi.org\/10.1007\/s10072-022-06074-z","DOI":"10.1007\/s10072-022-06074-z"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Ng CY, Tan BY, Teo YN, et al. Myocardial infarction, stroke and\n cardiovascular mortality among migraine patients: a systematic review and\n meta-analysis. J Neurol. 2022; 269: 2346-2358.\n https:\/\/doi.org\/10.1007\/s00415-021-10930-x","DOI":"10.1007\/s00415-021-10930-x"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Huang Y, Yan W, Jia Y, et al. Migraine and increased cardiovascular\n disease risk: interaction with traditional risk factors and lifestyle factors. J\n Headache Pain 2025; 26: 92.\n https:\/\/doi.org\/10.1186\/s10194-025-02002-6","DOI":"10.1186\/s10194-025-02002-6"},{"key":"R39","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the\n management of elevated blood pressure and hypertension. Eur Heart J. 2024; 45:\n 3912-4018. Erratum: Eur Heart J. 2025; 46: 1300."},{"key":"R40","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Standards of Care in Diabetes - 2023\n Abridged for Primary Care Providers. Clin Diabetes 2022; 41: 4-31. Erratum: Clin\n Diabetes 2023; 41: 328.\n https:\/\/doi.org\/10.2337\/cd23-er02a","DOI":"10.2337\/cd23-er02a"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Feh\u00e9r G, Pusch G. Role of antihypertensive drugs in the treatment of\n migraine. [V\u00e9rnyom\u00e1scs\u00f6kkent\u0151 szerek szerepe a migr\u00e9n kezel\u00e9s\u00e9ben.] Orv Hetil.\n 2015; 156: 179-185. [Hungarian]\n https:\/\/doi.org\/10.1556\/OH.2015.30056","DOI":"10.1556\/OH.2015.30056"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Bushnell C, Kernan WN, Sharrief AZ, et al. 2024 Guideline for the\n primary prevention of stroke: A guideline from the American Heart\n Association\/American Stroke Association. Stroke 2024; 55: e344-e424. Erratum:\n Stroke 2024; 55: e439.\n https:\/\/doi.org\/10.1161\/STR.0000000000000475","DOI":"10.1161\/STR.0000000000000475"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Straburzy\u0144ski M, Kopyt D, Marschollek K, et al. Increased infection\n risk in patients on preventive CGRP-targeting therapies. A meta-analysis and\n clinical effect assessment. J Headache Pain 2025; 26: 88.\n https:\/\/doi.org\/10.1186\/s10194-025-02040-0","DOI":"10.1186\/s10194-025-02040-0"},{"key":"R44","doi-asserted-by":"crossref","unstructured":"Ray JC, Allen P, Bacsi A, et al. Inflammatory complications of CGRP\n monoclonal antibodies: a case series. J Headache Pain 2021; 22: 121.\n https:\/\/doi.org\/10.1186\/s10194-021-01330-7","DOI":"10.1186\/s10194-021-01330-7"},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Iannone LF, Romozzi M, Russo A, et al. Association of\n anti-calcitonin gene-related peptide with other monoclonal antibodies for\n different diseases: a multicenter, prospective, cohort study. Eur J Neurol.\n 2024, 31: e16450. https:\/\/doi.org\/10.1111\/ene.16450","DOI":"10.1111\/ene.16450"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Diener HC, Antonaci F, Braschinsky M, et al. European Academy of\n Neurology guideline on the management of medication-overuse headache. Eur J\n Neurol. 2020; 27: 1102-1106.\n https:\/\/doi.org\/10.1111\/ene.14268","DOI":"10.1111\/ene.14268"},{"key":"R47","doi-asserted-by":"crossref","unstructured":"Gosalia H, Moreno-Ajona D, Goadsby PJ. Medication-overuse headache:\n a narrative review. J Headache Pain 2024; 25: 89.\n https:\/\/doi.org\/10.1186\/s10194-024-01755-w","DOI":"10.1186\/s10194-024-01755-w"},{"key":"R48","doi-asserted-by":"crossref","unstructured":"Sirilertmekasakul C, Panto A, Lekhalawan P, et al. The transition of\n medication overuse status by acute medication categories in episodic or chronic\n migraine patients to non-overuse status after receiving anti-CGRP monoclonal\n antibodies: a systematic review and meta-analysis of phase 3 randomized control\n trial. Neurol Sci. 2024; 45: 4451-4462.\n https:\/\/doi.org\/10.1007\/s10072-024-07496-7","DOI":"10.1007\/s10072-024-07496-7"},{"key":"R49","doi-asserted-by":"crossref","unstructured":"Diener HC, Kropp P, Dresler T, et al. Management of medication\n overuse (MO) and medication overuse headache (MOH) S1 guideline. Neurol Res\n Pract. 2022; 4: 37.\n https:\/\/doi.org\/10.1186\/s42466-022-00200-0","DOI":"10.1186\/s42466-022-00200-0"},{"key":"R50","doi-asserted-by":"crossref","unstructured":"Koonalintip P, Yamutai S, Setthawatcharawanich S, et al. Network\n meta-analysis comparing efficacy of different strategies on medication-overuse\n headache. J Headache Pain 2025; 26: 43. Erratum: J Headache Pain 2025; 26: 81.\n https:\/\/doi.org\/10.1186\/s10194-025-02031-1","DOI":"10.1186\/s10194-025-02031-1"},{"key":"R51","doi-asserted-by":"crossref","unstructured":"Rammohan K, Mundayadan SM, Das S, et al. Migraine and mood\n disorders: prevalence, clinical correlations and disability. J Neurosci Rural\n Pract. 2019; 10: 28-33.\n https:\/\/doi.org\/10.4103\/jnrp.jnrp_146_18","DOI":"10.4103\/jnrp.jnrp_146_18"},{"key":"R52","doi-asserted-by":"crossref","unstructured":"Hashikawa-Hobara N, Fujiwara K, Hashikawa N. CGRP causes anxiety via\n HP1\u03b3-KLF11-MAOB pathway and dopamine in the dorsal hippocampus. Commun Biol.\n 2024; 7: 322.\n https:\/\/doi.org\/10.1038\/s42003-024-05937-9","DOI":"10.1038\/s42003-024-05937-9"},{"key":"R53","doi-asserted-by":"crossref","unstructured":"Sal D, Perczel-Forintos D. Mindfulness-based cognitive therapy for\n individuals with chronic headaches. [Tudatos jelenl\u00e9t alap\u00fa kognit\u00edv ter\u00e1pia\n kr\u00f3nikus fejf\u00e1j\u00e1ssal \u00e9l\u0151k sz\u00e1m\u00e1ra.] Orv Hetil. 2024; 165: 1904-1910. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2024.33181","DOI":"10.1556\/650.2024.33181"},{"key":"R54","doi-asserted-by":"crossref","unstructured":"Lipton RB, Ramirez Campos V, Roth-Ben Arie Z, et al. Fremanezumab\n for the treatment of patients with migraine and comorbid major depressive\n disorder: the UNITE randomized clinical trial. JAMA Neurol. 2025; 82: 560-569.\n https:\/\/doi.org\/10.1001\/jamaneurol.2025.0806","DOI":"10.1001\/jamaneurol.2025.0806"},{"key":"R55","doi-asserted-by":"crossref","unstructured":"De Vries Lentsch S, van der Arend BW, et al. Depression and\n treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor)\n antibodies for migraine. Eur J Neurol. 2024; 31: e16106.\n https:\/\/doi.org\/10.1111\/ene.16106","DOI":"10.1111\/ene.16106"},{"key":"R56","doi-asserted-by":"crossref","unstructured":"Youn MS, Kim N, Lee MJ, et al. Treatment outcome after switching\n from galcanezumab to fremanezumab in patients with migraine. J Clin Neurol.\n 2024; 20: 300-305.\n https:\/\/doi.org\/10.3988\/jcn.2023.0311","DOI":"10.3988\/jcn.2023.0311"},{"key":"R57","doi-asserted-by":"crossref","unstructured":"Van Veelen N, van der Arend BW, Hiele E, et al. Switching from\n ligand to receptor anti-calcitonin gene-related peptide (CGRP) antibodies or\n vice versa in non-responders: a controlled cohort study. Eur J Neurol. 2025; 32:\n e16542. https:\/\/doi.org\/10.1111\/ene.16542","DOI":"10.1111\/ene.16542"},{"key":"R58","doi-asserted-by":"crossref","unstructured":"Triller P, Blessing VN, Overeem LH, et al. Efficacy of eptinezumab\n in non-responders to subcutaneous monoclonal antibodies against CGRP and the\n CGRP receptor: a retrospective cohort study. Cephalalgia 2024; 44:\n 3331024241288875.\n https:\/\/doi.org\/10.1177\/03331024241288875","DOI":"10.1177\/03331024241288875"},{"key":"R59","doi-asserted-by":"crossref","unstructured":"Lambru G, Caponnetto V, Hill B, et al. Long-term effect of switching\n from an anti-CGRP receptor to an anti-CGRP ligand antibody in\n treatment-refractory chronic migraine: a prospective real-world analysis.\n Neurotherapeutics 2023; 20: 1284-1293.\n https:\/\/doi.org\/10.1007\/s13311-023-01394-0","DOI":"10.1007\/s13311-023-01394-0"},{"key":"R60","doi-asserted-by":"crossref","unstructured":"Alsaadi T, Suliman R, Santos V, et al. Safety and tolerability of\n combining CGRP monoclonal antibodies with gepants in patients with migraine: a\n retrospective study. Neurol Ther. 2024; 13: 465-473.\n https:\/\/doi.org\/10.1007\/s40120-024-00586-w","DOI":"10.1007\/s40120-024-00586-w"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/50\/article-p1963.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/50\/article-p1963.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/50\/article-p1963.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:41:09Z","timestamp":1785494469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/50\/article-p1963.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":60,"journal-issue":{"issue":"50"},"URL":"https:\/\/doi.org\/10.1556\/650.2025.33427","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]}}}